- Home
- VLGEA vs GLUE Comparison
VLGEA vs GLUE Comparison
Compare VLGEA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- GLUE
- Stock Information
- Founded
- VLGEA 1937
- GLUE 2019
- Country
- VLGEA United States
- GLUE United States
- Employees
- VLGEA N/A
- GLUE N/A
- Industry
- VLGEA Food Chains
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- GLUE Health Care
- Exchange
- VLGEA Nasdaq
- GLUE Nasdaq
- Market Cap
- VLGEA 501.1M
- GLUE 407.3M
- IPO Year
- VLGEA N/A
- GLUE 2021
- Fundamental
- Price
- VLGEA $33.14
- GLUE $6.21
- Analyst Decision
- VLGEA
- GLUE Buy
- Analyst Count
- VLGEA 0
- GLUE 3
- Target Price
- VLGEA N/A
- GLUE $12.67
- AVG Volume (30 Days)
- VLGEA 33.4K
- GLUE 511.1K
- Earning Date
- VLGEA 03-04-2025
- GLUE 05-08-2025
- Dividend Yield
- VLGEA 3.02%
- GLUE N/A
- EPS Growth
- VLGEA 3.71
- GLUE N/A
- EPS
- VLGEA 3.65
- GLUE N/A
- Revenue
- VLGEA $2,281,980,000.00
- GLUE $14,975,000.00
- Revenue This Year
- VLGEA N/A
- GLUE N/A
- Revenue Next Year
- VLGEA N/A
- GLUE N/A
- P/E Ratio
- VLGEA $9.08
- GLUE N/A
- Revenue Growth
- VLGEA 3.96
- GLUE N/A
- 52 Week Low
- VLGEA $24.57
- GLUE $3.21
- 52 Week High
- VLGEA $35.34
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- VLGEA 53.18
- GLUE 50.13
- Support Level
- VLGEA $32.40
- GLUE $5.80
- Resistance Level
- VLGEA $34.48
- GLUE $6.70
- Average True Range (ATR)
- VLGEA 0.93
- GLUE 0.52
- MACD
- VLGEA 0.16
- GLUE 0.07
- Stochastic Oscillator
- VLGEA 65.64
- GLUE 66.21
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.